| 000 | 01757 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515060436.0 | ||
| 264 | 0 | _c20070501 | |
| 008 | 200705s 0 0 eng d | ||
| 022 | _a0143-3636 | ||
| 024 | 7 |
_a10.1097/MNM.0b013e328014a11e _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMoorin, Rachael E | |
| 245 | 0 | 0 |
_aPre-clinical evaluation of 2,3-dimercaptosuccinic acid as a radiation nephrotoxicity protective agent during radiopeptide therapy of neuroendocrine malignancy. _h[electronic resource] |
| 260 |
_bNuclear medicine communications _cApr 2007 |
||
| 300 |
_a261-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBody Burden |
| 650 | 0 | 4 |
_aChelating Agents _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 |
_aKidney _xmetabolism |
| 650 | 0 | 4 |
_aKidney Diseases _xetiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetabolic Clearance Rate _xdrug effects |
| 650 | 0 | 4 |
_aNeuroectodermal Tumors _xmetabolism |
| 650 | 0 | 4 |
_aOctreotide _xadministration & dosage |
| 650 | 0 | 4 | _aOrgan Specificity |
| 650 | 0 | 4 |
_aPeptides _xadministration & dosage |
| 650 | 0 | 4 | _aRadiation Dosage |
| 650 | 0 | 4 |
_aRadiation Injuries _xetiology |
| 650 | 0 | 4 |
_aRadiation-Protective Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aRadiopharmaceuticals _xadministration & dosage |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 |
_aSuccimer _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMeyrick, Danielle P | |
| 700 | 1 | _aRose, Alison | |
| 773 | 0 |
_tNuclear medicine communications _gvol. 28 _gno. 4 _gp. 261-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MNM.0b013e328014a11e _zAvailable from publisher's website |
| 999 |
_c16883306 _d16883306 |
||